MR

Millie Ray

Partner at The Column Group

United States

Overview

Work Experience

TC

The Column Group

  • Partner

    2022 - Current

  • Principal

    2019 - 2022

  • Associate

    2017 - 2018

Foghorn Therapeutics

  • Business Associate

    2016 - 2017

FV

Flagship Ventures - Venture Labs

  • Fellow and Associate

    2015 - 2016

MG

Massachusetts General Hospital

  • Graduate Student and Post- Doctoral Researcher- Kingston Lab

    2008 - 2015

BI

Broad Institute

  • Ebola Genomics team - Sabeti Lab

    2014 - 2015

    Implemented first Next Generation Sequencer to run in West Africa for high capacity Ebola surveillance and diagnostics tools.

Education

Investments

Casma Therapeutics

Series B

Total Funding: $160M

Hexagon Bio

Series A

Total Funding: $190M

Relevant Websites